European Patent EP3004337 Upheld by the EPO in Favor of Cellectis, Refers to the Method of Preparing T-Cells for Immunotherapy Using the RNA-Guided CRISPR-Cas9 Nuclease System

New York, NY (Press Release) – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a bio­pharma­ceu­tical com­pany focused on devel­op­ing immuno­therapies based on gene-edited allo­geneic CAR T-cells (UCART), today announced that European Patent EP3004337, which claims a method of preparing T-cells for immuno­therapy using the CRISPR-Cas9 sys­tem, initially granted on August 2, 2017, has been upheld by the European Patent Office (EPO) fol­low­ing an op­po­si­tion pro­ce­dure ini­ti­ated in May 2018.

European Patent EP3004337 claims a method of genetically modifying T-cells by in­tro­duc­tion into the cells and/or ex­pres­sion in the cells of an RNA-guided endonuclease, and …

• The com­pa­nies will con­tinue to col­lab­o­rate to discover and de­vel­op the next gen­er­a­tion of engi­neered alpha-beta T cells
• Editas Medicine to re­ceive a $70 million pay­ment and may be eli­gible for future mile­stone and royalty pay­ments

Cambridge, MA (Press Release) – Editas Medicine, Inc. (Nasdaq: EDIT), a lead­ing genome edit­ing com­pany, to­day an­nounced an amended col­lab­o­ration with Celgene Corpo­ra­tion (Nasdaq: CELG) under which the parties may re­search, de­vel­op, and com­mer­cial­ize au­tol­o­gous and allo­geneic alpha-beta T cell med­i­cines for the treat­ment of cancer and auto­immune dis­eases. Under the terms of the amended agree­ment, Editas Medicine will re­ceive a pay­ment of $70 million.

“Celgene is the leader in ad­vanc­ing inno­va­tive cell med­i­cines to treat blood cancers, and we are ex­cited to …

• Collaboration Includes Exclusive Rights and Targets for Initial Appli­ca­tions in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma
• Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus De­vel­op­ment and Commercial Milestones and Royalties on Net Sales

South San Francisco, CA and Toronto, ON (Press Release) – Allogene Thera­peutics, Inc. (Nasdaq: ALLO), a clin­i­cal-stage bio­technology com­pany pioneering the devel­op­ment of allo­geneic CAR T (AlloCAR T™) ther­a­pies for cancer, and Notch Thera­peutics Inc., an immune cell ther­apy com­pany creating universally compatible, allo­geneic T cell ther­a­pies for the treat­ment of dis­eases of high unmet need, to­day an­nounced an ex­clu­sive world­wide col­lab­o­ration and license agree­ment to re­search and de­vel­op induced pluripotent stem cell (iPSC) AlloCAR™ ther­apy prod­ucts for initial appli­ca­tion in non-Hodgkin lym­phoma, leukemia …

Toronto, ON (Press Release) – Notch Thera­peutics, a com­pany in the emerging field of gene-modified T cell ther­apy, has been created to com­mer­cial­ize a revolutionary tech­nology that creates allo­geneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making T cell ther­a­pies that are clin­i­cally robust and of a con­sis­tently high quality. Notch is actively pursuing industry part­ner­ships.

The founders of Notch - Sunnybrook Health Sciences Centre, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) and CCRM, with Lumira Ventures as an addi­tional in­vestor - created Notch to provide …

Cellectis’ UCARTCS1 MELANI-01 Trial Commenced at MD Anderson Cancer Center

New York, NY (Press Release) – Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a bio­pharma­ceu­tical com­pany focused on devel­op­ing immuno­therapies based on gene-edited off-the-shelf CAR T-cells (UCART), to­day an­nounced the Com­pany has dosed the first patient in its UCARTCS1 clin­i­cal trial, MELANI-01, the first allo­geneic off-the-shelf CAR-T prod­uct can­di­date the U.S. Food and Drug Admin­istra­tion (FDA) has cleared to enter into clin­i­cal devel­op­ment for re­lapsed / re­frac­tory mul­ti­ple myeloma (R/R MM). The UCARTCS1 clin­i­cal trial is a Phase 1 dose-escalation study to eval­u­ate the safety, ex­pan­sion, persistence and clin­i­cal ac­­tiv­ity of UCARTCS1 cells …

Shanghai, China (Press Release) – CARsgen Thera­peutics Co. Ltd., a clin­i­cal-stage bio­pharma­ceu­tical com­pany to­day an­nounced that the United States Food and Drug Admin­istra­tion (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) desig­na­tion to its inves­ti­ga­tional CT053 CAR-T cell ther­apy. CT053 is a fully human anti-BCMA (B Cell Maturation Antigen) au­tol­o­gous chi­meric an­ti­gen re­cep­tor (CAR) T Cell ther­apy for the treat­ment of re­lapsed and/or re­frac­tory mul­ti­ple myeloma (rrMM).

RMAT desig­na­tion was based on clin­i­cal data from an on­go­ing CT053 phase 1 study in heavily pre-treated mul­ti­ple myeloma patients in China. Updated data from CT053 …

Gaithersburg, MD (Press Release) – Arcellx, a privately-held bio­pharma­ceu­tical com­pany, to­day an­nounced that it has raised $85 million in an oversubscribed Series B financing. Proceeds will be used to ad­vance the Com­pany’s ARC-T + sparX pro­grams, in­clud­ing clin­i­cal devel­op­ment of a bivalent BCMA-targeted cell ther­apy in mul­ti­ple myeloma, and a CD123-targeted ther­apy in acute myeloid leukemia. The Series B will also fund earlier stage ARC-T + sparX pro­grams for patients with solid tumors and dis­eases outside on­col­ogy.

Participants in the Series B in­clude both existing and new in­vestors to Arcellx. New in­vestors Aju …